Prostate Cancer

Leslie R. Schover, professor of behavioral science, The University of Texas MD Anderson Cancer Center, discusses information and education for patients regarding sexuality after treatment.

Leslie R. Schover, professor of behavioral science, The University of Texas MD Anderson Cancer Center, discusses some problems men face after cancer treatment.

New diagnoses of prostate cancer have declined nearly 30 percent, a study has found, since the U.S. Preventive Services Task Force discouraged the routine use of prostate-specific antigen testing in 2011.

An online tool is designed to help men with prostate or other types of cancer deal with sexual dysfunction and other common side effects of treatment.

Photographer Bill Aron discusses his book.

Photographer Bill Aron tells his prostate cancer story.

Clinical development of prostate cancer vaccines is moving forward.

When the USPSTF issued its recommendation against PSA testing, urologists nationwide, myself included, warned about the possible public health repercussions that could ensue. Our fears have materialized, and much sooner than anticipated.

Adding the chemotherapy docetaxel to standard combination hormonal and radiation therapy boosted survival rates in patients with high-risk localized prostate cancer, according to a study.

Data from a new report that shows compelling information on physicians who use Twitter, types of cancer, and ways to assess integrity.

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Although use of robotic surgery for prostate cancer has surpassed open surgical procedures in number, the impact of this approach on patient quality of life has not been well-studied.

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.

Surgery has its side effects, says radiation oncologist Richard Stock, including possible incontinence and sexual dysfunction. While radiation is less invasive, it does have its own side effects.

Treatment with Xtandi reduced the risk of progression by 76 percent compared with bicalutamide in men with castration-resistant prostate cancer, according to topline results from the phase 2 STRIVE study.

The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.